

**MTN 039 - Safety and PK Study of TAF/EVG Administered Rectally  
Data as of December 5, 2022**

**Visit Adherence: Completion of Procedures During Enrollment and Follow-up<sup>1</sup> by Site**

	<b>Pittsburgh</b>	<b>Birmingham</b>	<b>All Sites</b>
Participants Enrolled	11	12	23
1. Behavioral Assessment Required and Expected	30	32	62
Completed	30 (100.0%)	32 (100.0%)	62 (100.0%)
2. In-depth Interview Required and Expected	9	9	18
Completed	8 (88.9%)	9 (100.0%)	17 (94.4%)
Not Completed	1 (11.1%)	0 (0.0%)	1 (5.6%)
3. Physical Exams Required and Expected	11	12	23
Completed	11 (100.0%)	12 (100.0%)	23 (100.0%)
4. Rectal Exam Required and Expected	77	82	159
Completed	77 (100.0%)	82 (100.0%)	159 (100.0%)
5. Pregnancy Test Required and Expected	3	2	5
Completed	3 (100.0%)	2 (100.0%)	5 (100.0%)
6. Hematology Required and Expected	9	9	18
Completed	9 (100.0%)	9 (100.0%)	18 (100.0%)
7. Differentials Required and Expected	9	9	18
Completed	9 (100.0%)	9 (100.0%)	18 (100.0%)
8. Blood Chemistries Required and Expected	9	9	18
Completed	9 (100.0%)	9 (100.0%)	18 (100.0%)
9. Plasma for Archive Required and Expected	11	12	23
Completed	11 (100.0%)	12 (100.0%)	23 (100.0%)

<sup>1</sup> Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 039 - Safety and PK Study of TAF/EVG Administered Rectally  
Data as of December 5, 2022**

**Visit Adherence: Completion of Procedures During Enrollment and Follow-up<sup>1</sup> by Site**

	<b>Pittsburgh</b>	<b>Birmingham</b>	<b>All Sites</b>
10. Plasma for PK Required and Expected	87	93	180
Completed	86 (98.9%)	93 (100.0%)	179 (99.4%)
Not Completed	1 (1.1%)	0 (0.0%)	1 (0.6%)
11. HIV-1/2 Tests Required and Expected	20	21	41
Completed	20 (100.0%)	21 (100.0%)	41 (100.0%)
12. CVF for PK Required and Expected (Female Only)	20	10	30
Completed	20 (100.0%)	10 (100.0%)	30 (100.0%)
13. CVF for PD Required and Expected (Female Only)	20	10	30
Completed	19 (95.0%)	10 (100.0%)	29 (96.7%)
Not Completed	1 (5.0%)	0 (0.0%)	1 (3.3%)
14. CVF for Microflora Required and Expected (Female Only)	12	6	18
Completed	12 (100.0%)	6 (100.0%)	18 (100.0%)
15. Rectal Fluid for PD Required and Expected	49	52	101
Completed	49 (100.0%)	52 (100.0%)	101 (100.0%)
16. Rectal Fluid for PK Required and Expected	49	50	99
Completed	49 (100.0%)	50 (100.0%)	99 (100.0%)
17. Rectal Tissue for PD Required and Expected	49	52	101
Completed	48 (98.0%)	52 (100.0%)	100 (99.0%)
Not Completed	1 (2.0%)	0 (0.0%)	1 (1.0%)
18. Rectal Tissue for PK Required and Expected	38	40	78
Completed	37 (97.4%)	40 (100.0%)	77 (98.7%)
Not Completed	1 (2.6%)	0 (0.0%)	1 (1.3%)

<sup>1</sup> Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 039 - Safety and PK Study of TAF/EVG Administered Rectally  
Data as of December 5, 2022**

**Visit Adherence: Completion of Procedures During Enrollment and Follow-up<sup>1</sup> by Site**

	<b>Pittsburgh</b>	<b>Birmingham</b>	<b>All Sites</b>
19. Rectal Fluid for Microbiome Required and Expected	30	32	62
Completed	30 (100.0%)	32 (100.0%)	62 (100.0%)
20. Rectal Tissue for Biomarkers Required and Expected	30	32	62
Completed	30 (100.0%)	32 (100.0%)	62 (100.0%)

<sup>1</sup> Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.